Scientific news

Pharmaceutical giants are sidestepping US marijuana restrictions to research cannabis-based drugs

Federal policies restricting marijuana research have made it difficult to study marijuana and produce cannabis-based drugs - but that isn't stopping pharmaceutical companies from doing it.

How Jefferson Health Birthed the United States' First Major Cannabis Research Program

The medical cannabis program in Pennsylvania is about to enter unprecedented territory as it embarks on the nation’s first state-sanctioned research program.

The Latest in Cannabis Research: Spring 2018

Trying to keep track of all the advances in medical cannabis research? Here are some brief summaries of some of the biggest headlines over the last few months

European Doctors Call for Cannabis Medicines to be Mainstreamed.

The European Journal of Internal Medicine (EJIM) has published a special issue for March titled "Cannabis in Medicine."

MMJ BioScience Licensed in Canada to Make Cannabis-based Medicine for Huntington’s Studies

MMJ BioScience to Make Cannabis-based Medicine for Huntington's.

MMJ BioScience has been licensed in Canada to produce cannabis-derived medicines for testing in FDA-approved studies for Huntington’s disease.

More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy.

Cannabinoids are effective as an adjunctive treatment for reducing seizure frequency in pediatric-onset treatment-resistant epilepsy.

CBD may help curb frequency of epileptic seizures

Naturally occurring compound found in cannabis may help to curb the frequency of epileptic seizures,

Zelda Therapeutics expands pancreatic cancer research with Curtin University

Treatment with cannabinoid-based extracts could be an alternative to chemotherapy

A Physician's perspective on optimal cannabis dosing

Dosage is the key factor in achieving the most benefits and least adverse effects of cannabis

GW's cannabinoid fails in focal seizures trial

A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.